EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review

Zakhi Zafrani iD, Sarah Suleman Khan, Michael Zitzmann

Cells · 23.07.2026 · 15 (15) · 1319

DOI: 10.3390/cells15151319 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cells, online erschienen am 23.07.2026. Verfasst von Zakhi Zafrani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Manchester SK8 6HD, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypogonadism, Reproduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Testosterone deficiency is highly prevalent in men with obesity and type 2 diabetes mellitus and often reflects functional suppression of the hypothalamic–pituitary–gonadal (HPG) axis. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in these conditions, but their effects on male reproductive endocrinology remain incompletely defined.

Objective

To systematically review the effects of GLP-1 receptor agonists on testosterone, HPG axis hormones, and male reproductive outcomes.

Methods

A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE, Cochrane, and Google Scholar were searched (January 2021–January 2026) for studies evaluating GLP-1 RA therapy in adult men with reported endocrine or reproductive outcomes.

Results

Eight studies met inclusion criteria, including one randomised placebo-controlled crossover trial and six observational or interventional studies. In men with obesity, type 2 diabetes, or functional hypogonadism, GLP-1 RAs were associated with modest increases in testosterone and improvements in erectile function or selected semen parameters. In contrast, a placebo-controlled trial in healthy eugonadal men showed no significant endocrine or reproductive effects. Responses appeared dependent on baseline metabolic status.

Conclusions

GLP-1 RAs are associated with improvements in male reproductive endocrinology in metabolically compromised populations with metabolic hypogonadism while remaining neutral in healthy individuals. Larger prospective studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHypogonadismReproductionHumansMaleTestosteroneHypothalamic-Pituitary-Gonadal AxisDiabetes Mellitus, Type 2Obesity

Stichwörter der Autor:innen

GLP-1 receptor agonistsfunctional hypogonadismmale reproductive endocrinologymetabolic healthobesitytestosterone deficiency

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsTestosterone

Autor:innen und Institutionen

  • Independent Researcher, Manchester SK8 6HD, UK.
  • Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Münster University Hospital, 48149 Munster, Germany.

ORCID-Profile: Zakhi Zafrani

Zitieren

APA

Zafrani, Z., Khan, S. S., & Zitzmann, M. (2026). Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review. Cells, 15(15), 1319. https://doi.org/10.3390/cells15151319

Vancouver

Zafrani Z, Khan SS, Zitzmann M. Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review. Cells. 2026;15(15):1319. doi:10.3390/cells15151319

BibTeX
@article{Zafrani2026,
  author = {Zafrani, Zakhi and Khan, Sarah Suleman and Zitzmann, Michael},
  title = {Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {15},
  pages = {1319},
  doi = {10.3390/cells15151319}
}
Kostenlos starten →